Vanguard Group Incs Strategic Reduction in Amylyx Pharmaceuticals Inc Shares
AMLX Etf | USD 3.78 0.06 1.56% |
Slightly above 62% of Amylyx Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Amylyx Pharmaceuticals etf suggests that many investors are alarmed at this time. Amylyx Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Amylyx Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Amylyx |
Overview of Recent Transaction On September 30, 2024, Vanguard Group Inc executed a significant transaction involving Amylyx Pharmaceuticals Inc , where t
Read at gurufocus.com
Amylyx Pharmaceuticals Fundamental Analysis
We analyze Amylyx Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amylyx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amylyx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Amylyx Pharmaceuticals is currently under evaluation in shares owned by institutions as compared to similar ETFs. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Amylyx Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Amylyx Pharmaceuticals etf to make a market-neutral strategy. Peer analysis of Amylyx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Amylyx Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Amylyx Pharmaceuticals Related Equities
ABOS | Acumen Pharmaceuticals | 7.56 | ||||
PDSB | PDS Biotechnology | 6.13 | ||||
INZY | Inozyme Pharma | 2.89 | ||||
XFOR | X4 Pharmaceuticals | 2.74 | ||||
TERN | Terns Pharmaceuticals | 2.35 | ||||
DAWN | Day One | 0.32 | ||||
MREO | Mereo BioPharma | 0.57 | ||||
HOOK | Hookipa Pharma | 2.99 |
Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.